Equillium (EQ)
(Delayed Data from NSDQ)
$0.84 USD
+0.01 (0.95%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $0.84 0.00 (-0.36%) 6:42 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Price, Consensus and EPS Surprise
EQ 0.84 +0.01(0.95%)
Will EQ be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for EQ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EQ
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates
Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
EQ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
5 Stocks That More Than Doubled in Q1 With More Gains Ahead
Other News for EQ
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
EQ Inc. Reports Second Quarter Financial Results
Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)